The Extramammary Paget disease market was valued at USD 204.41 million in 2021 and is expected to reach USD 308.98 million by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029.
Extramammary Paget Disease Market Dynamics
Drivers
- Rising prevalence of Extramammary Paget disease
The surging prevalence of Extramammary Paget disease is a major factor driving the market's growth rate during the forecast period of 2022-2029. A pluripotent keratinocyte stem cell, Taker cell, or apocrine gland duct cell could be the cell of origin in primary extramammary Paget disease.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of Extramammary Paget disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Opportunities
- Increase in the number of research and development activities
The market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Extramammary Paget disease market growth.
Restraints/Challenges
On the other hand, high cost associated with the available treatment and diagnosis will obstruct the growth rate of the market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the Extramammary Paget disease market.
Patient Epidemiology Analysis
EMPD is a rare disease, with just a few hundred instances described in the medical literature worldwide. The exact frequency is unknown. EMPD accounts for 6.5 percent of all cutaneous Paget disease cases and primarily affects patients aged 50 to 80, with a peak age of 65.3 years.
Get sample report here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-extramammary-paget-disease-market
Market Definition
Extramammary Paget disease (EPMD) is an uncommon condition characterized by a chronic skin rash in the vaginal areas that looks like eczema. Needle biopsy or ultrasound screening of regional lymph nodes are needed tests, as is the search for other malignancies using procedures such as colonoscopy, cervical smear, or mammography.
Global Extramammary Paget Disease Market Scope
The Extramammary Paget disease market is segmented on the basis of type, route of administration, diagnosis, treatment, end-users and distribution channel. Type 1
- Type 2
- Type 3
Route of Administration
- Oral
- Topical
- Parenteral
- Others
Diagnosis
- Needle Biopsy
- Ultrasound
- Colonoscopy
- Cervical Smear
- Mammography
Treatment
- Surgery
- Cryotherapy
- Mohs micrographic surgery
- Excisional biopsy
- Vulvectomy
- Radiation Therapy
- Aminolaevulinic Acid Based Photodynamic Therapy
- Laser Ablation
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Competitive Landscape and Extramammary Paget Disease Market Share Analysis
The Extramammary Paget disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Extramammary Paget disease market.
Some of the major players operating in the Extramammary Paget disease market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikmah Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Rd. Reddy’s Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
- Allergan (Ireland)
Get toc of report https://www.databridgemarketresearch.com/toc/?dbmr=global-extramammary-paget-disease-market
MAJOR TOC OF THE REPORT
Ø Chapter One: Introduction
Ø Chapter Two: Market Dynamics
Ø Chapter Three: Market Definition
Ø Chapter Four: Market Scope
Ø Chapter Five: Market Share Analysis
Get Full Access Report https://www.databridgemarketresearch.com/reports/global-extramammary-paget-disease-market
Browse Related Reports
Global Women's Health Market – Industry Trends and Forecast to 2029
Global Smart Healthcare Market – Industry Trends and Forecast to 2029
Global Contract Research Organization (CROs) Services Market – Industry Trends and Forecast to 2029
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
